The Scottish Medicines Consortium (SMC) has issued advice on eight different medicines, advising healthcare professionals as to whether they have been accepted for use, accepted for restricted use, or not recommended for use in NHS Scotland.
The medicines are listed under the following British National Formulary categories:
- glycopyrronium bromide—accepted for use.
Central nervous system
- aprepitant—accepted for use.
- saxagliptin/dapagliflozin fixed dose combination—accepted for restricted use.
- ustekinumab—accepted for use.
Malignant disease and immunosuppression
The SMC aims to ensure that newly licensed medications representing good value for money are accepted for routine use in NHS Scotland as quickly as possible. It does this by bringing together a consortium that is made up of lead clinicians, pharmacists, and health economists, as well as representatives from health boards, the pharmaceutical industry, and the public.